Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Sep 30;12(10):e9392.
doi: 10.1002/ccr3.9392. eCollection 2024 Oct.

Triple therapy approach for treating chromoblastomycosis in a Lebanese patient

Joe Khodeir  1 , Paul Ohanian  2 , Hala Abi Rached Megarbane  3
Affiliations

Triple therapy approach for treating chromoblastomycosis in a Lebanese patient

Joe Khodeir et al. Clin Case Rep. .

Abstract

Chromoblastomycosis, though rare in non-endemic regions like Lebanon, should be considered in patients presenting with chronic, verrucous skin lesions unresponsive to conventional therapies. Multimodal treatment combining oral antifungals, cryotherapy, and adjunctive topical 5-Fluorouracil demonstrates efficacy in managing refractory cases. Follow-up visits three and 6 months after treatment cessation showed sustained lesion clearance and no recurrence.

Keywords: chromoblastomycosis; dermatological treatment; fungal infection; infectious dermatology; tropical skin infection.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
(A, B) Hyperkeratotic erythematous nodular lesions with secondary ulceration and pustules. (C) Four weeks after initial presentation, the lesion became more hyperkeratotic and exophytic in appearance, with overlying (D) black dots on the surface of the lesion, representing sclerotic bodies.
FIGURE 2
FIGURE 2
Numerous muriform/sclerotcic bodies seen on KOH examination.
FIGURE 3
FIGURE 3
Three months after triple therapy lesions improved drastically.
See this image and copyright information in PMC

References

    1. Queiroz‐Telles F, de Hoog S, Santos DWCL, et al. Chromoblastomycosis. Clin Microbiol Rev. 2017;30(1):233‐276. doi:10.1128/CMR.00032-16 - DOI - PMC - PubMed
    1. Brito ACD, Bittencourt MDJS. Chromoblastomycosis: an etiological, epidemiological, clinical, diagnostic, and treatment update. An Bras Dermatol. 2018;93(4):495‐506. doi:10.1590/abd1806-4841.20187321 - DOI - PMC - PubMed
    1. Alam W, Mobayed T, Younis N, et al. Neglected tropical diseases in Lebanon. Acta Parasitol. 2022;67(2):809‐819. doi:10.1007/s11686-021-00510-4 - DOI - PMC - PubMed
    1. Shenoy M, Girisha B, Krishna S. Chromoblastomycosis: a case series and literature review. Indian Dermatol Online J. 2023;14(5):665‐669. doi:10.4103/idoj.idoj_292_23 - DOI - PMC - PubMed
    1. Sarangi G. Chromoblastomycosis: a neglected tropical disease. Med J Dr Patil Vidyapeeth. 2021;14(2):234. doi:10.4103/mjdrdypu.mjdrdypu_73_19 - DOI

LinkOut - more resources